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Abstract
Psoriasis is a chronic immune-mediated inflammatory skin disease with both genetic and envi-
ronmental factors contributing to its pathogenesis. Transforming Growth Factor beta (TGFβ) is 
a member of a large family of pleiotropic cytokines with three different isoforms (TGFβ1,2,3). 
Smads are a family of eight-related proteins that function as intracellular signaling intermedi-
ates for TGFβ once the latter is bound to its receptors (TGFbRI, II and III). The involvement of 
Smads in TGFβ signaling has been studied intensively in the skin in the process of wound heal-
ing. Few studies, and with controversial results, have investigated at the immunohistochemical 
and molecular level the role of TGFβ/Smads signaling in psoriasis. 
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Psoriasis is a chronic immune-mediated inflammatory cutaneous disease affect-
ing 2-4% of the general population. Epidemiological studies revealed that a distinct 
group of comorbidities are significantly associated with psoriasis, such as cardio-
vascular disease, diabetes, obesity, hypertension, metabolic syndrome, dyslipidemia, 
inflammatory bowel diseases, non-alcoholic fatty acid disease, anxiety and depression 
(Christophers, 2001; Gelfand et al., 2006; Azfar and Gelfand, 2008; Davidovici et al., 
2010; Mehta et al., 2011; Nijsten and Stern, 2012; Skroza et al. 2013).
Clinically, psoriasis appears with well-demarcated, erythematous and scaly 
plaques (Fig. 1), histopathologically characterized by thickening of the epider-
mis, incomplete cornification with retention of nuclei in the stratum corneum, and 
elongated rete ridges (Fig. 2). Dilated vessels are observed in the papillary dermis 
and a perivascular infiltrate composed of CD4+ T cells, dendritic cells (DC) and 
monocytes⁄macrophages is present in the upper papillary dermis and one of CD8+ T 
cells and neutrophilic granulocytes in the epidermis.
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The exact pathogenesis of psoriasis remains to be fully determined, but both envi-
ronmental and genetic factors seem to be responsible for the dysregulation of innate 
and adaptive immune response in psoriatic skin.
Classic genome linkage analysis has identified at least 10 chromosomal regions 
(termed PSORS1 to PSORS10) with statistically significant linkage to psoriasis (Perera 




Figure 2 – Psoriatic skin (A) shows increased thickness of the epidermis and an inflammatory infiltrate in 
dermis, compared to control skin (B). Haematoxylin and eosin, 10x.
Figure 1 – Clinical manifestations of moderate to severe chronic plaque psoriasis (A, B).
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within the major histocompatibility complex, with the HLA-Cw*060 allele being the 
most likely candidate as PSORS1 gene. Furthermore, genome-wide association stud-
ies have recently identified about 12 genes with various functions involved in pso-
riasis development (Perera et al., 2012). Notably, several of these psoriasis-associated 
genes belong to the interleukin (IL)-23/Th17 axis, the nuclear factor κB (NF-κB) sign-
aling pathway and the epidermal differentiation complex, suggesting that these path-
ways might be critically involved in the pathogenesis of psoriasis.
In a genetically predisposed individual, all cells located in the epidermis and der-
mis that are involved in the maintenance of barrier integrity can determine a dysreg-
ulated response to either an environmental or a self-antigenic insult. An initial trig-
ger such as physical trauma or bacterial products can induce a cascade of events that 
include the formation of complexes of the antimicrobial peptide cathelicidin LL-37 
and DNA, activation of plasmacytoid dendritic cells (pDCs), and secretion of interfer-
on (IFN)-α. By inducing pDC activation, LL-37–self-DNA complexes initiate a patho-
genic cross-talk between stressed epidermal cells and recruited pDCs and induce a 
proinflammatory cytokine cascade including TNF-α, IL-6, and IL-1β released by 
keratinocytes. Activated pDCs migrate into draining lymph nodes and induce the dif-
ferentiation of naive CD4+ T cells into effector cells such as Th1 and Th17 and cyto-
toxic T cells that produce interleukin-17 (Tc17). Immune effector cells migrate to the 
skin attracted by the keratinocyte-derived chemokines and infiltrate the skin. Moreo-
ver, inflammatory myeloid DCs produce TNF-α, nitric oxide radicals and IL-23. IL-23 
sustains the proliferation of activated Th17 cells producing IL-17 and IL-22, while 
Th1 cells express IFN-γ and TNF-α (Sabat, 2007; Perera et al., 2012). The resulting 
cytokine milieu of IFNγ, TNF-α, IL-17 and IL-22 affects keratinocytes, increasing their 
proliferation and stimulating the production of pro-inflammatory cytokines and the 
neutrophil-recruiting chemokines that in turn sustain and amplify the chronic inflam-
matory disease process (Perera et al., 2012).
Among all cytokines and growth factors, trasforming growth factor β (TGFβ) plays 
a role in sustaining and amplifying the inflammatory response by producing a variety 
of proinflammatory mediators important for the development of psoriatic lesions and 
then for activating the vicious cycle necessary to perpetuate the pathogenetic process. 
TGFβ is a member of a large family of pleiotropic cytokines, with three different iso-
forms (TGFβ1,2,3) found in mammals. TGFβ intracellular signal transduction pathway 
is mediated mainly by Smad proteins (Derynck and Zhang, 2003; Roberts et al., 2003). 
Smads are a family of eight related proteins that function as signaling interme-
diates for the TGFβ superfamily members. Upon ligation and activation of TGFβ 
with its receptors (I, II and III), the phosphorylated Smad2 and Smad3 bind to the 
common mediator Smad4. The Smad2/Smad3-Smad4 complex translocates into the 
nucleus where it regulates specific TGFβ target genes. The inhibitory Smad7 antago-
nizes TGFβ signaling by competing with ligation of Smad2/3 to the activated recep-
tor complex (Fig. 3).
The TGFβs have been implicated in various inflammatory diseases such as liv-
er cirrhosis (Inagaki and Okazaki, 2007), nephritis (Inazaki et al., 2004), pulmonary 
fibrosis (Lawrence, 1996), inflammatory bowel diseases (Crohn’s disease and ulcera-
tive colitis) (Latella et al., 2009) and scleroderma (Lakos et al., 2004). Several experi-
mental studies have also demonstrated that the disruption of the TGFβ/Smads sign-
aling, owing to loss of Smad3 or an increase of Smad7 expression, confers resistance 
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to tissue fibrosis in many organs (Inazaki et al., 2004; Latella et al., 2009). As far as 
cancer is concerned, mutations of TGFβ receptors have been reported in human squa-
mous cell carcinoma cell lines (Ichijo et al., 1990; Reiss and Stash, 1990) and decreased 
levels of TGFβRI or TGFβRII have been shown in a variety of neoplastic lesions 
including colon (Markowitz et al., 1995) and gastric cancers (Takenoshita et al., 1997).
The involvement of Smads in TGFβ signaling has been also studied intensively 
in the skin, especially in the process of wound healing. Here, TGFβ has been demon-
strated to play a central role in inhibiting the growth of keratinocytes and in stimu-
lating the growth of fibroblasts (Pittelkow et al., 1988; Cutroneo, 2007). Experimental 
studies in Smad3 knock-out mice showed that wound healing is accelerated, while 
local inflammatory responses are decreased (Ashcroft et al., 1999; Yu et al., 2009). 
Despite this important influence of TGFβ on the homeostasis of human tissues, 
including normal skin, there have been only a few and controversial studies on the 
role of TGFβ/Smads signaling in the pathogenesis of psoriasis. 
Immunohistochemical analysis of TGFβ1 showed both in normal and psoriatic 
skin an immunopositivity of the suprabasal keratinocytes (Kane et al., 1990). Selective 
association of TGFβ1 with non-proliferating keratinocytes in the suprabasal layers of 
the epidermis and its exclusion from the proliferating keratinocytes in the basal layer 
suggests that it may be a physiological regulator of keratinocyte proliferation. The 
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Figure 3 – TGFβ/Smad pathway.
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suggests that it is constitutively synthesized by epidermal keratinocytes in vivo (Kane 
et al., 1990).  Since TGFβ1 was detected in the dermis as well as in the epidermis 
in several sections of both plaque and non-plaque skin from psoriatic patients, there 
may be additional sites of TGFβ1 synthesis in the psoriatic dermis or the distribution 
of keratinocyte-derived TGFβ1 may be altered in psoriatic skin (Kane et al, 1990). 
Conversely, other Authors reported that TGFβ1 was detected in neither epidermis nor 
dermis in both normal and psoriatic skin while TGFβ2 was found in the intercellular 






Figure 4 – TGFβ1 is expressed in the basal layer of the epidermis in normal skin (A) while there is no evi-
dence of immunoexpression in the epidermis of psoriatic skin (C). TGFβRI is present both in the basal layer of 
the epidermis and widely spread in connective tissue of dermis of normal skin (B). In psoriatic skin TGFβRI is 
only present in connective tissue of dermis (D). Immunohistochemistry, 40x.
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mis; in contrast, TGFβ3 was present in the subepidermal area of the psoriatic skin 
as in the normal human skin (Wataya-Kaneda et al., 1996). Since TGFβ is a potent 
growth inhibitor of human keratinocytes, the decrease of TGFβ2 in the epidermis of 
psoriatic skin may contribute to epidermal hyperplasia, a hallmark of psoriasis. 
As TGFβ has an antiproliferative role on the epidermis, TGFβ receptors (TGFβR) are 
needed to mediate this effect. Leivo et al. (1998) observed intense immunohistochemi-
cal staining for both receptors in basal and suprabasal epidermal keratinocytes in skin 
from healthy subjects and non-lesional psoriatic skin, but no staining in the epidermis 
of lesional psoriatic skin. A significant reduction of TGFβ receptors in psoriatic epider-
A B 25 µm 
TGFβ1 TGFβ2 TGFβRI TGFβRII SMAD 2, 4, 6 SMAD 3 
 KANE et al., 
1990  = 
WATAYA-
KANEDA et al., 
1996 
= ↓ 
 YU et al.,  
2009 = = ↓ ↑ ↓ 
GAMBICHLER  
et al., 2013 ↑ ↓ ↑ 
Tab.1 
MARKER EXPRESSIONS IN PSORIATIC SKIN VS NORMAL SKIN 
Figure 6 – Expression of different markers in psoriasis vs. normal healthy skin.
Figure 5 – Positive staining for Smad3 is located in basal keratinocytes and is widely spread in the con-
nective tissue of dermis of normal skin (A); no evidence of immunoreaction for Smad3 in psoriatic skin (B). 
Immunohistochemistry, 40x.
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mis and the decreased expression of both TGFβ receptors (TGFβRI and TGFβRII) could 
be a reason for diminished perception of TGFβ1 signaling (Leivo et al., 1998). 
By investigating the expression of TGFβ1, 2 and 3 and their receptors both in 
lesional and non lesional psoriatic skin compared to skin from healthy subjects by 
real time PCR, no differences in TGFβ1 and 2 mRNA levels were found between pso-
riatic and normal skin; upregulation of TGFβ3 mRNA only in non-lesional psoriat-
ic skin may be responsible for inhibiting epidermal hyperproliferation. In the same 
cases TGFβRI was downregulated together with Smad 2, 4 and 6 mRNA expression, 
confirming the crucial role of these receptors in the pathogenesis of the disease (Yu 
et al.,2009). On the other hand, Gambichler et al. (2013) observed increased mRNA 
levels for TGFβ1 as well as Smad3, while confirming decreased mRNA levels for 
TGFβRI in psoriatic skin (Tab. 1)
The role of TGFβ/Smads signaling in the pathogenesis of psoriasis is supported 
by the efficacy of current therapeutic strategies, known to impact this pathway. The 
beneficial effect of 1α, 25-dihydroxyvitamin D3 (active derivative of vitamin D3) in 
psoriasis seems to be mediated at least in part by TGFβ and Smad signaling (Yanagi 
et al., 1999; Yanagisawa et al., 1999; Oyama et al., 2000; Yu et al., 2009). Other Authors 
have shown that UVB blocks in vitro cellular responsiveness to TGFβ through down-
regulation of TGFβRII receptor and induction of Smad 7 (Quan et al., 2002).
We recently performed an immunohistochemical study on the role of TGFβ/
Smads signaling in psoriasis in a limited number of samples. Our results demonstrat-
ed a downregulation of TGFβ1 and TGFβRI in the epidermis of all psoriatic speci-
mens compared to control skin, which showed a marked immunopositivity in the 
basal keratinocytes and in the connective tissue of  the dermis (Fig. 4). Our data also 
revealed a decreased expression of Smad 3 in basal keratinocytes of psoriatic skin 
compared to control skin (Fig. 5). 
Further studies are needed to better clarify the role of TGFβ/Smads signaling in 
the pathogenesis of psoriasis, in order to highlight whether it is directly involved in 
the development of disease and, therefore, might be a promising therapeutic target of 
antipsoriatic drugs in the future. 
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